Eli Lilly and Company $LLY Shares Acquired by Stanley Laman Group Ltd.

Key Points

• Stanley Laman Group Ltd. raised its stake in Eli Lilly by 70.1% in Q4, adding 2,665 shares to hold 6,465 shares worth about $6.95M, and institutional investors now own roughly 82.53% of the stock.
• Key growth catalysts include strong demand expectations for Lilly’s newly launched obesity pill, the acquisition of CrossBridge Bio (up to $300M) to bolster oncology options, expanded distribution for its oral GLP‑1 and licensing of the TuneLab AI platform.
• Financials remain strong: quarterly results beat estimates (EPS $7.54 vs. $7.48; revenue $19.29B, +42.6% YoY), management set FY 2026 guidance of 33.50–35.00 EPS, and analysts maintain a "Moderate Buy" consensus with an average target near $1,224.59.

Stanley Laman Group Ltd. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 70.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,465 shares of the company's stock after purchasing an additional 2,665 shares during the quarter. Eli Lilly and Company comprises 0.9% of Stanley Laman Group Ltd.'s portfolio, making the stock its 24th largest position. Stanley Laman Group Ltd.'s holdings in Eli Lilly and Company were worth $6,948,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company's stock worth $61,771,785,000 after purchasing an additional 551,659 shares during the period. State Street Corp raised its position in shares of Eli Lilly and Company by 0.6% during the 3rd quarter. State Street Corp now owns 34,726,558 shares of the company's stock worth $26,496,364,000 after purchasing an additional 219,590 shares during the period. Capital Research Global Investors raised its position in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Wellington Management Group LLP raised its position in shares of Eli Lilly and Company by 4.1% during the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company's stock worth $11,112,164,000 after purchasing an additional 574,229 shares during the period. Finally, Capital International Investors raised its position in shares of Eli Lilly and Company by 6.1% during the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company's stock worth $7,628,447,000 after purchasing an additional 579,381 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly received another buy rating tied to its newly launched obesity pill, which analysts expect to be a global bestseller — this supports revenue upside from weight‑loss therapies. Eli Lilly Stock (LLY) Gets Another Buy Rating as Its Obesity Pill Hits the Market
• Positive Sentiment: Lilly agreed to acquire CrossBridge Bio for up to $300M, adding preclinical ADC technology to bolster oncology pipeline optionality and long‑term growth prospects. Lilly to acquire CrossBridge Bio for up to $300m
• Positive Sentiment: Distribution and access expand as digital care platform Shed adds Foundayo™ (Lilly’s oral GLP‑1 for weight management), which can help broaden patient uptake beyond specialty clinics. Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide
• Positive Sentiment: Lilly is licensing its TuneLab AI platform to partners (e.g., Vasa Therapeutics), highlighting additional revenue streams and R&D leverage from proprietary AI tools. Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform
• Neutral Sentiment: Macro/valuation commentary remains mixed — some bullish, long‑term price targets (e.g., Forbes piece on LLY to $2,000) reflect confidence in blockbuster drugs but are speculative. LLY Stock To $2,000?
• Neutral Sentiment: Market reports note the stock is down today despite broader market gains — a short‑term price action update for traders. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: Competitive risk is rising: Novo Nordisk’s new partnership with OpenAI to accelerate drug discovery reinforces its capability to close gaps in the weight‑loss market and may pressure Lilly’s market share and investor sentiment. NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $905.73 on Thursday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The firm has a market capitalization of $855.75 billion, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 1.07 and a beta of 0.51. The business has a 50 day simple moving average of $976.09 and a 200 day simple moving average of $979.89. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm's quarterly revenue was up 42.6% on a year-over-year basis. During the same period last year, the company posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Sanford C. Bernstein reiterated an "outperform" rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 6th. Daiwa Securities Group increased their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a research report on Wednesday, February 18th. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $875.00 to $880.00 and gave the stock a "neutral" rating in a report on Friday, April 10th. Finally, Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the stock a "buy" rating in a report on Friday, March 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,224.59.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.